The increase in production of drugs from its own substances – the strategic goal of JSC “Joint-stock Kurgan society of medical drugs and products... “Synthesis” is developing a R&D center for the development of substances

The increase in production of drugs from its own substances – the strategic goal of JSC “Joint-stock Kurgan society of medical drugs and products “Synthesis” (included in Marathon Pharma and “national immunobiological company”) in the medium term.

To solve this problem, the company invests in the development of own R&D center. So, in August was launched the laboratory complex freeze-and spray drying, designed for development of the technology of production of substances.

The complex allows you to experiment with even 1 gram of matter with the aim of creating connections and optimizing processes of production of substances.

Thanks to the development of own R&D center, the company plans to significantly expand the portfolio of drugs produced on a full cycle, and increase the proportion of such drugs by half by 2025.

The laboratory is a smaller version of working on the “Synthesis” plant for the production of substances whose performance is tens of tons of substances a year. Informed the development of a new process in an industrial environment took from six to twelve months, the laboratory setup will allow to shorten the start-up period of three to four times in a short period of time to increase the production of substances for the production of its own medicines, and for sale to external counterparties.

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *